Clinical trial
SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen…
NCT00361244 · Massachusetts General Hospital, Other · Terminated
Key facts
| NCT number | NCT00361244 |
|---|---|
| Title | SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer |
| Official title | A Phase I/II Study of SU011248 (Sutent) in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Patients With Stage IV Colorectal Cancer |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Carcinoma |
| Intervention type | Drug |
| Interventions | SU011248, Irinotecan, Cetuximab |
| Enrollment | 6 |
| Start date | Jul 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Aug 1, 2010 |
| First posted | Aug 8, 2006 |
| Last update posted | Feb 17, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: